Compare Expedia Group Inc (EXPE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Revvity Inc — how do they compare? Expedia Group Inc trades at $322.49 (market cap $38.53B), while Revvity Inc trades at $116.1 (market cap $12.91B). The key difference: Expedia Group Inc is far larger — about 3× Revvity Inc's market cap, and Expedia Group Inc pays the higher dividend (0.6%). Which is the better fit depends on your goals.
| EXPE | RVTY | |
|---|---|---|
Market Cap | $38.53B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $321.07 | $117.75 |
52-Week Low | $188.51 | $82.26 |
Enterprise Value | $37.09B | $15.23B |
Dividend Yield | 0.6% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $321.5, up 2.39% today, with strong technical momentum and a bullish moving average crossover. The company reported robust Q2 2026 earnings, beating estimates with EPS of $5.76 versus $5.22 expected, driven by 14% revenue growth and record adjusted EBITDA of $1.1 billion (Business Wire, 2026-08-05). Fundamentals show high profitability with a 90.43% gross margin and improving net income, while valuation ratios like P/E of 20.19 and P/S of 2.59 reflect market confidence.
Outlook is positive with raised full-year revenue guidance to $16.05B-$16.22B (WSJ, 2026-08-05), supported by AI and B2B growth. Risks include competitive pressures and economic sensitivity. Analysts are mixed but lean bullish with a $322.95 consensus target, near the current price, suggesting limited upside but stability.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
